US EditionEli Lilly's Oral GLP-1 Pill Matches Injectables, Eyes Approval by Year-End
- Eli Lilly announced today at the American Diabetes Association meeting that its daily pill orforglipron showed effective weight loss and blood sugar reduction in a Phase 3 trial involving type 2 diabetes patients.
- The trial tested three doses over 40 weeks in 559 patients and aimed to confirm orforglipron's efficacy comparable to injectable GLP-1 drugs like Ozempic and tirzepatide.
- The highest dose led to nearly 8% weight loss and blood sugar levels dropped 1.3% to 1.6%, with gastrointestinal side effects similar to other GLP-1 medications including diarrhea and vomiting.
- Ken Custer, Lilly's president of cardiometabolic health, emphasized that orforglipron's oral administration and easier storage could help expand access to weight-loss treatments worldwide.
- Lilly intends to submit regulatory filings for orforglipron as a weight management treatment by the end of 2025 and aims to do the same for its use in diabetes care in 2026, while continuing studies to assess its impact on individuals without diabetes.
30 Articles
30 Articles
Hastings Tribune
Leader-TelegramLilly’s experimental obesity pill holds up to scrutiny in trial
Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s competition with Novo Nordisk A/S.
Eli Lilly posts detailed late-stage trial data for oral weight loss drug orforglipron
Eli Lilly (NYSE:LLY) on Saturday announced detailed data from its ACHIEVE-1 Phase 3 trial, which reached the main goal for its oral weight loss therapy, orforglipron, in patients with type 2 diabetes early this year.
Lilly expects orforglipron obesity results in third quarter
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes.
Lilly Expects Orforglipron Obesity Results in Third Quarter
Rutland Herald
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes
Coverage Details
Bias Distribution
- 56% of the sources are Center
To view factuality data please Upgrade to Premium
